Filing Details

Accession Number:
0001415889-24-010001
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-04-03 16:22:48
Reporting Period:
2024-04-01
Accepted Time:
2024-04-03 16:22:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1649094 Vaxcyte Inc. PCVX Biological Products, (No Disgnostic Substances) (2836) 464233385
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1918033 Mikhail Eydelman C/O Vaxcyte, Inc.
825 Industrial Road, Suite 300
San Carlos CA 94070
Svp, Gen Counsel & Corp Sec No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-04-01 1,667 $21.41 32,264 No 4 M Direct
Common Stock Disposition 2024-04-01 1,397 $66.59 30,867 No 4 S Direct
Common Stock Disposition 2024-04-01 270 $67.42 30,597 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2024-04-01 1,667 $0.00 1,667 $21.41
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
188,332 2032-05-08 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023.
  2. The price reported is a weighted-average price. The shares were sold at prices ranging from $66.185 to $67.13. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. The price reported is a weighted-average price. The shares were sold at prices ranging from $67.37 to $68.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  4. 1/4 of the shares subject to the option shall vest on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.